CN107536804A - Fexofenadine hydrochloride dry suspensoid agent and preparation method thereof - Google Patents
Fexofenadine hydrochloride dry suspensoid agent and preparation method thereof Download PDFInfo
- Publication number
- CN107536804A CN107536804A CN201610477785.0A CN201610477785A CN107536804A CN 107536804 A CN107536804 A CN 107536804A CN 201610477785 A CN201610477785 A CN 201610477785A CN 107536804 A CN107536804 A CN 107536804A
- Authority
- CN
- China
- Prior art keywords
- fexofenadine hydrochloride
- dry suspensoid
- preparation
- suspensoid agent
- fexofenadine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to fexofenadine hydrochloride dry suspensoid agent and preparation method thereof, active constituents of medicine is fexofenadine hydrochloride, it is characterised in that the component including following percentage by weight is prepared:Fexofenadine hydrochloride 1% ~ 3%, filler 20% ~ 70%, flavouring 20% ~ 70%, glidant 0.1% ~ 0.5%, suspending agent 0.3% ~ 0.8%, adhesive 3% ~ 9%, cosolvent 0.5% ~ 2%.A kind of fexofenadine hydrochloride dry suspensoid agent of the present invention solves the patient compliance sex chromosome mosaicism in use of Fexofenadine customization agent in background technology, the fexofenadine hydrochloride preparation that suitable old man children and dysphagia patients use in providing, and solid dispersions solution is employed in preparation and is pelletized, both it is small to have solved this product content, caused content problem of non-uniform, it is poor also to solve this product dissolubility simultaneously, the problem of caused dissolution is slow.
Description
Technical field
The present invention relates to field of medicine preparations, more particularly to a kind of antihistamine, more particularly to fexofenadine hydrochloride is done
Supensoid agent and preparation method thereof.
Background technology
Fexofenadine hydrochloride is a kind of second generation H1 receptor antagonists, be mainly used in treat seasonal allergic rhinitis and
Chronic idiopathic urticaria.The people that the whole world has 40% or so at present suffers from anaphylactia, and wherein children's quantity is most.Hydrochloric acid is non-
Fexofenadine is treatment allergic rhinitis, the new drug of chronic idiopathic urticaria.It is the active generation of resistance amine medicine RMI 9918
Thank to product, eliminate parent Fei Nading cardiac toxic, it is impossible to which through blood-brain barrier, body absorption is fast, and oral rear 1-1.5 is small
When reach Cmax, half-life period is 11-14 hours.Fexofenadine hydrochloride, which removes, possesses the excellent of second generation histamine H 1 receptor antagonist
Outside point, following advantage is also equipped with:1)Mechanism of action is clear and definite;2)Long half time, long action time;3)Not by liver metabolism, energy
It is used safely in the patient of hepatic disorder, to liver not damaged;4)Action character is obvious:Fexofenadine hydrochloride is to allergia nose
Scorching and better tolerance effective with Chronic Spontaneous nettle rash, has certain suppression to make to skin rash block and flush caused by histamine
With;5)Adverse reaction is light less, there are no cardiac toxic.
Have fexofenadine hydrochloride preparation both at home and abroad at present to be approved to list, the formulation that foreign countries ratify listing is tablet, glue
Capsule, suspension and the compound preparation with pseudoephedrine, the formulation of country's approval listing is tablet and capsule, but is not had both at home and abroad
The dry suspensoid agent for having fexofenadine hydrochloride reports.
As the extension of average human life and age increase the decline of swallow, oral tablet administration mode turns into
A problem of concern.According to statistics, there is 50% patient not feel well for preparation prescription to answer;The patient for having 35% feels
Tablet and capsule are difficult to swallow or have dysphagia, particularly the elderly and children this wide range of crowd, have impact on medicine
The compliance for the treatment of.In paediatrics, gerontal patient crowd, population proportion increasingly increases, so the field is to Oral Dry Suspensions type
There is widespread demand.The incidence of disease of current global anaphylactia increasingly raises, wherein most with children's quantity.Fexofenadine hydrochloride
Being scheduled on the formulation of domestic approval listing includes tablet and capsule, there is no a kind of suitable child patient, gerontal patient, aphetite disorder to suffer from
The new oral formulation that the special populations such as person use.Moreover, the dosage very little of fexofenadine hydrochloride preparation, the uniformity of preparation
It is poor, while the dissolubility of this product is poor, dissolution is slow.
The content of the invention
It is an object of the invention to provide it is a kind of it is easy to use, dissolubility is good, the fexofenadine hydrochloride of preparation good evenness
Determine dry suspensoid agent.
Another object of the present invention is to provide a kind of preparation method of fexofenadine hydrochloride dry suspensoid agent.
In order to solve problem present in background technology, foregoing invention purpose is realized, the present invention adopts the following technical scheme that:
Fexofenadine hydrochloride dry suspensoid agent,
Fexofenadine hydrochloride dry suspensoid agent, its active constituents of medicine are fexofenadine hydrochloride, including following percentage by weight
Component be prepared:Fexofenadine hydrochloride 1% ~ 3%, filler 20% ~ 70%, flavouring 20% ~ 70%, glidant 0.1% ~
0.5%th, suspending agent 0.3% ~ 0.8%, adhesive 3% ~ 9%, cosolvent 0.5% ~ 2%.
Described filler is mannitol.
Described adhesive is sodium carboxymethylcellulose or PVP K30 or its mixing.
Described suspending agent is xanthans, carragheen, Arabic gum, gelatin, sodium carboxymethylcellulose, cross-linked carboxymethyl fibre
Tie up one or more mixing in plain sodium, PVP, pectin, guar gum, sodium alginate.
Described flavouring is that the one or more in sucrose, lactose, starch, mannitol, saleratus, cellulose family are mixed
Close.
The invention also discloses a kind of preparation method of fexofenadine hydrochloride dry suspensoid agent, the fexofenadine hydrochloride
The preparation method of dry suspensoid agent comprises the following steps to be prepared:
(1), weigh fexofenadine hydrochloride and adhesive by recipe quantity, add the ethanol of recipe quantity 95%, stirring and dissolving, contained
Drug solns are standby;
(2), filler, cosolvent are weighed by recipe quantity, be placed in multi-functional granulator coater top spray device, open equipment, add
Enter the above-mentioned drug solns that contain and carry out top spray granulation, pellet through sieves whole grain is made, then mix with additional suspending agent, glidant, flavouring
Close uniformly, subpackage dress, produce.
A kind of fexofenadine hydrochloride dry suspensoid agent of the present invention solves Fexofenadine customization agent in background technology and used
In patient compliance sex chromosome mosaicism, there is provided the fexofenadine hydrochloride preparation for being adapted to old man children and dysphagia patients to use,
And solid dispersions solution is employed in preparation and is pelletized, both solve that this product content is small, and caused content is uneven asks
The problem of topic, while it is poor also to solve this product dissolubility, caused dissolution are slow.
Embodiment
Below by embodiment, the present invention is described further.
Embodiment 1:
Fexofenadine hydrochloride dry suspensoid agent is prepared, using following prescription:(Unit:g)
And it is prepared using following preparation method:
1st, fexofenadine hydrochloride, polyoxyethylene sorbitan monoleate and PVP K30 are weighed by recipe quantity, adds recipe quantity 95%
Ethanol, stirring and dissolving obtain drug containing solution for standby;
2nd, mannitol, sucrose, microcrystalline cellulose and sodium carboxymethylcellulose are weighed by recipe quantity, is placed in multi-functional granulator coater
In top spray device, equipment is opened, the drug solns that contain that step 1 obtains is added and carries out top spray granulation, it is whole that obtained particle crosses 24 mesh sieves
Grain, then be well mixed with additional xanthans, Abbas's sweet tea, essence and silica, subpackage, which fills, to be produced.
2nd, mannitol, sucrose, microcrystalline cellulose and sodium carboxymethylcellulose are weighed by recipe quantity, is wrapped as multi-functional granulation
In clothing machine top spray device, equipment to be opened, the above-mentioned drug solns that contain is added and carries out top spray granulation, obtained particle crosses 24 mesh sieve whole grains, then
It is well mixed, subpackage dress, produces with additional xanthans, Aspartame, essence and silica.
Fexofenadine hydrochloride dry suspensoid agent made from the present embodiment, solid dispersions solution is employed in preparation process
Pelletized, solve the problems, such as that the small caused content of active constituents of medicine content is uneven, while also solve this product dissolving
The problem of property is poor, and bioavilability is not high.
Embodiment 2:
Fexofenadine hydrochloride dry suspensoid agent is prepared, using following prescription:
Name of material | Dosage | Ratio | Purposes |
Fexofenadine hydrochloride | 10.0 | 1% | Active component |
Mannitol | 598 | 59.8% | Filler |
Lactose | 200.0 | 20% | Flavouring |
Microcrystalline cellulose | 100.0 | 10% | Filler |
Sodium carboxymethylcellulose | 50.0 | 3% | Adhesive |
PVP K30 | 10.0 | 3% | Adhesive |
Polyoxyethylene sorbitan monoleate | 12.0 | 1.2% | Cosolvent |
Sodium alginate | 5.0 | 0.5% | Suspending agent |
Aspartame | 5.0 | 0.5% | Flavouring |
Essence | 8.0 | 0.8% | Essence |
Silica | 2.0 | 0.2% | Glidant |
Preparation method and embodiment 1 are identical.
Claims (6)
1. fexofenadine hydrochloride dry suspensoid agent, its active constituents of medicine is fexofenadine hydrochloride, it is characterised in that including such as
The component of lower percentage by weight is prepared:Fexofenadine hydrochloride 1% ~ 3%, filler 20% ~ 70%, flavouring 20% ~ 70%
, glidant 0.1% ~ 0.5%, suspending agent 0.3% ~ 0.8%, adhesive 3% ~ 9%, cosolvent 0.5% ~ 2%.
2. fexofenadine hydrochloride dry suspensoid agent according to claim 1, it is characterised in that described filler is sweet dew
Alcohol, microcrystalline cellulose or its combination.
3. fexofenadine hydrochloride dry suspensoid agent according to claim 1, it is characterised in that described adhesive is carboxylic first
Base sodium cellulosate or PVP K30 or its mixing.
4. fexofenadine hydrochloride dry suspensoid agent according to claim 1, it is characterised in that described suspending agent is xanthan
Glue, carragheen, Arabic gum, gelatin, sodium carboxymethylcellulose, Ac-Di-Sol, PVP, pectin, Gua Ershu
One or more mixing in glue, sodium alginate.
5. fexofenadine hydrochloride dry suspensoid agent according to claim 1, it is characterised in that described flavouring be sucrose,
One or more mixing in lactose, starch, mannitol, saleratus, cellulose family.
6. according to the preparation method of fexofenadine hydrochloride dry suspensoid agent described in claim 1 ~ 5 any one, it is characterised in that
Comprise the following steps to be prepared:
(1), weigh fexofenadine hydrochloride and adhesive by recipe quantity, add the ethanol of recipe quantity 95%, stirring and dissolving, contained
Drug solns are standby;
(2), filler, cosolvent are weighed by recipe quantity, be placed in multi-functional granulator coater top spray device, open equipment, add
Enter the above-mentioned drug solns that contain and carry out top spray granulation, pellet through sieves whole grain is made, then mix with additional suspending agent, glidant, flavouring
Close uniformly, subpackage dress, produce.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610477785.0A CN107536804A (en) | 2016-06-28 | 2016-06-28 | Fexofenadine hydrochloride dry suspensoid agent and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610477785.0A CN107536804A (en) | 2016-06-28 | 2016-06-28 | Fexofenadine hydrochloride dry suspensoid agent and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107536804A true CN107536804A (en) | 2018-01-05 |
Family
ID=60961493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610477785.0A Pending CN107536804A (en) | 2016-06-28 | 2016-06-28 | Fexofenadine hydrochloride dry suspensoid agent and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107536804A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115715759A (en) * | 2022-11-03 | 2023-02-28 | 京海盛达(北京)科技有限公司 | Anti-histamine suspension and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080274196A1 (en) * | 2005-08-05 | 2008-11-06 | Lipin Limited | Oral Pharmaceutical Suspension Compositions Of Fexofenadine |
CN101537184A (en) * | 2009-04-30 | 2009-09-23 | 杭州中美华东制药有限公司 | Composition containing water-insoluble high-activity drug and preparation method thereof |
US20130344116A1 (en) * | 2012-06-26 | 2013-12-26 | Magnifica Inc. | Oral particle consisting of an amorphous structure and a submicron domain |
CN103610645A (en) * | 2013-11-25 | 2014-03-05 | 浙江万马药业有限公司 | Pharmaceutical composition with fexofenadine hydrochloride and preparation method of pharmaceutical composition |
-
2016
- 2016-06-28 CN CN201610477785.0A patent/CN107536804A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080274196A1 (en) * | 2005-08-05 | 2008-11-06 | Lipin Limited | Oral Pharmaceutical Suspension Compositions Of Fexofenadine |
CN101537184A (en) * | 2009-04-30 | 2009-09-23 | 杭州中美华东制药有限公司 | Composition containing water-insoluble high-activity drug and preparation method thereof |
US20130344116A1 (en) * | 2012-06-26 | 2013-12-26 | Magnifica Inc. | Oral particle consisting of an amorphous structure and a submicron domain |
CN103610645A (en) * | 2013-11-25 | 2014-03-05 | 浙江万马药业有限公司 | Pharmaceutical composition with fexofenadine hydrochloride and preparation method of pharmaceutical composition |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115715759A (en) * | 2022-11-03 | 2023-02-28 | 京海盛达(北京)科技有限公司 | Anti-histamine suspension and preparation method thereof |
CN115715759B (en) * | 2022-11-03 | 2024-01-12 | 京海盛达(北京)科技有限公司 | Antihistamine suspension and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Caddeo et al. | Chitosan–xanthan gum microparticle-based oral tablet for colon-targeted and sustained delivery of quercetin | |
TWI222885B (en) | Extended release oral dosage composition | |
TWI225414B (en) | Stable extended release oral dosage composition | |
CN101583620A (en) | Ganaxolone formulations and methods for the making and use thereof | |
ZA200509669B (en) | Use of a compound in the treatment of sleep disorders | |
MX2008016115A (en) | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone. | |
CN103813785A (en) | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence | |
JP2000505094A (en) | Treatment of upper respiratory allergic response using a combination of histamine receptor antagonists | |
TW200522980A (en) | Drug-including particle and solid drug formulation comprising said particle | |
CN105534933A (en) | Vortioxetine orally disintegrating tablet and preparation method thereof | |
EP3813831B1 (en) | Extended release compositions comprising trihexyphenidyl | |
CN106389360A (en) | Directly-compressed tablet of dapoxetine hydrochloride and preparation method thereof | |
WO2021030607A1 (en) | Pimavanserin for treating neurodegenerative diseases | |
CN103520169B (en) | Mirtazapine tablet and preparation method thereof | |
CN107536804A (en) | Fexofenadine hydrochloride dry suspensoid agent and preparation method thereof | |
EP3515413B1 (en) | Extended relief dosage form | |
CN101152155A (en) | Hydrochloric acid Ivabradine solid pharmaceutical composition and method for preparing the same | |
WO2007010930A1 (en) | Drug-containing coated fine particle for intrabuccally disintegrating preparation and method of producing the same | |
JP3341770B1 (en) | Jelly agent containing branched-chain amino acid | |
MXPA05004412A (en) | Sustained-release tramadol formulations with 24-hour efficacy. | |
JP2003512330A (en) | Ciclesonide-containing aqueous pharmaceutical composition | |
CN106420738A (en) | Sustained release preparation of levamlodipine besylate tablets or salts thereof and preparation method of sustained release preparation | |
CN105708808A (en) | Epinastine hydrochloride granule, and preparation method thereof | |
Adi-Dako et al. | Potential of Cocoa Pod Husk Pectin‐Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague‐Dawley Rats | |
CN108014098A (en) | A kind of tolvaptan fast release micropill preparation, preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180105 |
|
WD01 | Invention patent application deemed withdrawn after publication |